The Objectives of This Chapter Are To

Total Page:16

File Type:pdf, Size:1020Kb

The Objectives of This Chapter Are To The objectives of this chapter are to: N Describe the steps of membrane synthesis. N Outline the process of peptidoglycan synthesis. N Introduce the concepts of protein structure and function. N Highlight important aspects of protein synthesis and export. N Describe the structure and function of cell appendages. © 2007 Sinauer Associates, Inc. This material cannot be copied, reproduced, manufactured, or disseminated in any form without express written permission from the publisher. 11 Assembly of Bacterial Cell Structures ...Topologically, all the layers of the envelope are closed surfaces and must be physically continuous for cell integrity and viability to be maintained. ...All the constituents of the envelope must grow coordinately and with special regard to their location... The overall process is similar in gram-positive and gram-negative bacteria but differs in detail... —Neidhardt, Ingraham and Schaechter, Physiology of the Bacterial Cell: A Molecular Approach, 1990 he generation of precursor metabolites and the reactions that convert these to the monomeric building blocks of a cell were Tdiscussed in Chapter 10. The precursor metabolites originate ei- ther from CO2 fixation, gluconeogenesis, the tricarboxylic acid cycle, glycolysis, or allied pathways. Through a limited number of well-in- tegrated reactions, the major monomers—including the amino acids, nucleotides, sugars, and fatty acids—are synthesized from these pre- cursors. Rapid and orderly growth depends on the polymerization or assembly of monomeric building blocks to form macromolecules. Among the essential polymerization reactions are the formation of proteins from amino acids, polysaccharides from sugars, and nucleic acids from nucleotides. Phospholipids are derived from fatty acids. Once formed, macromolecules (DNA, RNA, proteins, and phospho- lipids) are assembled to generate a cell (Figure 11.1). Note that pro- teins and RNA make up the major part of a living cell. The actual number of molecules of each macromolecular component present in an Escherichia coli cell is listed in Table 11.1. Replication of DNA, RNA synthesis, and the role of the nucleic acids in protein synthesis will be discussed in Chapter 13. The follow- ing is a brief discussion of the synthesis and assembly of cell mem- branes and protein structures and the assembly and export of con- stituents to the cell envelope (peptidoglycan layers), outer membrane (in gram-negative bacteria), plus cell appendages. © 2007 Sinauer Associates, Inc. This material cannot be copied, reproduced, manufactured, or disseminated in any form without express written permission from the publisher. 288 Chapter Eleven The precursor …the types of monomers, Further reactions …that interact to metabolites formed in or building blocks, of all polymerize the produce the structures glycolysis, the TCA cellular components. monomers to form that make up the E. coli cycle, and related macromolecules… cell. pathways enter biosynthetic pathways that produce… Lipids Fatty acids ˜8 Lipopolysaccharides Inclusion 2– Glycogen bodies Glucose-6-phosphate PO4 Sugars ˜25 Fructose-6-phosphate + Peptidoglycan Envelope Pentose-5-phosphate HS– Erythrose-4-phosphate + 2– PO4 Glycerol-3-phosphate NH3 Flagella 3-Phosphoglycerate Glucose Phosphoenolpyruvate Amino acids Fueling Biosynthetic Pyruvate ˜25 Protein Pili reactions Acetyl-CoA reactions α-Ketoglutarate Succinyl-CoA Cytosol Oxaloacetate Poly- Nucleotides 8 ribosomes Figure 11.1 Synthesis of cell structures from glucose ˜ RNA An overview of the anabolic reactions that lead from glu- Nucleoid cose to the structures in an E. coli cell. The numbers of dif- DNA ferent monomer types needed are indicated; the size of Polymerization Assembly each box is proportional to the amount of material required reactions by an E. coli cell. The overall macromolecular composition of an TABLE 11.1 Escherichia coli cell Percentage of Number of Types of Total Dry Weight Molecules Molecules Molecule of Cell per Cell Possible Protein 55.0 2,360,000 ~4200 RNA 20.5 23S rRNA 18,700 1 16S rRNA 18,700 1 Perry Staley Lory Microbiology 2/e 5S rRNA 18,700 1 Sinauer Associates transfer RNA 205,000 ~60 Elizabeth Morales Illustration Services Figure 11.01.eps Date 02-16-07 messenger RNA Variable ~1,380 DNA 3.1 ~2.1 1 Lipida 9.1 22,000,000 4 Lipopolysaccharide 3.4 1,200,000 1 Peptidoglycan 2.5 1 1 Glycogen 2.5 4,360 1 Soluble organic poolb 2.9 Large ~850 Inorganic poolc 1.0 Large ~20 aThe phospholipids are of four general classes, which may exist in a variety of types based on fatty acid chain. bMetabolites, vitamins, and precursors. cAnions, cations. Adapted from Neidhardt, Ingraham, and Schaechter, 1990. © 2007 Sinauer Associates, Inc. This material cannot be copied, reproduced, manufactured, or disseminated in any form without express written permission from the publisher. Assembly of Bacterial Cell Structures 289 11.1 Membrane Synthesis able cell may be controlled by proteins in the membrane. This process may require ATP, but that is uncertain at One structure that is present in all Bacteria and Archaea the present time. is the cytoplasmic membrane, also called the cell mem- Modification of bacterial membranes can occur inde- brane. The basic structure of a cytoplasmic membrane pendently of cell growth and division. A constant was described in Chapter 4 (see Figures 4.44 and 4.45); turnover of membrane proteins or phospholipids (or it serves as the primary boundary of the cell’s cytoplasm. both) occurs as organisms adjust to changing environ- The bacterial cytoplasmic membrane is similar in its ba- mental conditions. Cells increase the proportion of mem- sic structure to other membranes—for example, those brane unsaturated fatty acids as a response to a decrease surrounding eukaryotic cells, nuclei, mitochondria, and in growth temperature. This occurs because a functional other organelles. The membranes of Archaea are quite membrane must be fluid and because the double bonds different, as will be discussed in Chapter 18. in unsaturated fatty acids are more fluid at lower temper- A cytoplasmic membrane in a growing cell must as- atures. A cell may also vary the fatty acid chain length. In similate new membrane components (phospholipids and E. coli, C18 fatty acids are more abundant at high growth proteins) and integrate these into the membrane, which temperatures, while C16 predominates at lower temper- is increasing in surface area. During integration of the atures. Newly formed solute transport proteins or respi- newly synthesized phospholipids, the permeability and ratory enzymes may also be inserted into the cytoplasmic barrier functions of the membrane must be maintained. membrane as a microorganism encounters a different sub- strate or other changes in growth conditions. Synthesis of Lipids Membrane lipids compose about 10% of the cell dry SECTION HIGHLIGHTS weight (see Table 11.1) and thus represent a considerable Assembly of phospholipids occurs at the sur- expenditure of cell energy. Enzymes for lipid synthesis are face of the cytoplasmic membrane and re- generally located in the cytoplasmic membrane with the quires the carrier molecule ACP. The lipid and exception of those needed for precursor biosynthesis (glyc- protein composition of a cell may be adjusted erol-3-phosphate) and fatty acid synthesis; these are dis- independently of cell growth in order to adapt cussed in Chapter 10. Since lipid types differ among bac- to temperature and nutritional changes. teria with respect to fatty acid chain length, saturation, and polar head group, the reader is directed to advanced text- books and scientific literature for detailed information. As a general plan, long-chain fatty acids (C14–18) are assem- bled in the cytoplasm from acetyl-CoA precursor mole- 11.2 Peptidoglycan Synthesis cules via small acyl-carrier protein (ACP) intermediates. The degree of fatty acid saturation may vary depending Peptidoglycan (murein) is the main structural compo- on the cell growth condition; the fatty acids are then ester- nent of the bacterial cell wall. It is the source of strength ified with glycerol at the inner surface of the cytoplasmic and provides the characteristic cell size and shape. The membrane. A polar head group is then added to join two composition, structure, and function of peptidoglycan fatty acids, yielding the mature phospholipid (see Figure in both gram-positive and gram-negative bacteria were 4.45). E. coli, for example contains three types of phospho- discussed in Chapter 4. The position beyond the cyto- lipids (phosphatidylglycerol, phosphatidylethanolamine, plasmic membrane (Figure 11.2) presents interesting and cardiolipin (diphosphatidylglycerol), where the polar questions regarding its synthesis and assembly. head groups are glycerol, ethanolamine, and phos- The assembly of peptidoglycan precursor units oc- phatidylglycerol, respectively. Other microbes, for exam- curs in the cytoplasm and the cytoplasmic membrane ple Bacillus subtilis, may contain different head groups: (Figure 11.3). At the inner surface of the cell membrane, glucose and glucose—O—glucose in addition to ethan- both N-acetylglucosamine (NAG) and N-acetylmuramic olamine and glycerol. acid (NAM) are synthesized and then coupled to bac- The newly synthesized phospholipids are incorpo- toprenol (undecaprenol phosphate, Udc; Figure 11.4). rated into the inner leaflet of the cytoplasmic membrane Bactoprenol is a long-chain hydrocarbon that can enter bilayer, and in a relatively short time appear in the outer the hydrophobic core
Recommended publications
  • Synthesis and Biological Evaluation of Trisindolyl-Cycloalkanes and Bis- Indolyl Naphthalene Small Molecules As Potent Antibacterial and Antifungal Agents
    Synthesis and Biological Evaluation of Trisindolyl-Cycloalkanes and Bis- Indolyl Naphthalene Small Molecules as Potent Antibacterial and Antifungal Agents Dissertation Zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) Vorgelegt der Naturwissenschaftlichen Fakultät I Institut für Pharmazie Fachbereich für Pharmazeutische Chemie der Martin-Luther-Universität Halle-Wittenberg von Kaveh Yasrebi Geboren am 09.14.1987 in Teheran/Iran (Islamische Republik) Gutachter: 1. Prof. Dr. Andreas Hilgeroth (Martin-Luther-Universität Halle-Wittenberg, Germany) 2. Prof. Dr. Sibel Süzen (Ankara Üniversitesi, Turkey) 3. Prof. Dr. Michael Lalk (Ernst-Moritz-Arndt-Universität Greifswald, Germany) Halle (Saale), den 21. Juli 2020 Selbstständigkeitserklärung Hiermit erkläre ich gemäß § 5 (2) b der Promotionsordnung der Naturwissenschaftlichen Fakultät I – Institut für Pharmazie der Martin-Luther-Universität Halle-Wittenberg, dass ich die vorliegende Arbeit selbstständig und ohne Benutzung anderer als der angegebenen Hilfsmittel und Quellen angefertigt habe. Alle Stellen, die wörtlich oder sinngemäß aus Veröffentlichungen entnommen sind, habe ich als solche kenntlich gemacht. Ich erkläre ferner, dass diese Arbeit in gleicher oder ähnlicher Form bisher keiner anderen Prüfbehörde zur Erlangung des Doktorgrades vorgelegt wurde. Halle (Saale), den 21. Juli 2020 Kaveh Yasrebi Acknowledgement This study was carried out from June 2015 to July 2017 in the Research Group of Drug Development and Analysis led by Prof. Dr. Andreas Hilgeroth at the Institute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg. I would like to thank all the people for their participation who supported my work in this way and helped me obtain good results. First of all, I would like to express my gratitude to Prof. Dr. Andreas Hilgeroth for providing me with opportunity to carry out my Ph.D.
    [Show full text]
  • Novel Antimicrobial Agents Inhibiting Lipid II Incorporation Into Peptidoglycan Essay MBB
    27 -7-2019 Novel antimicrobial agents inhibiting lipid II incorporation into peptidoglycan Essay MBB Mark Nijland S3265978 Supervisor: Prof. Dr. Dirk-Jan Scheffers Molecular Microbiology University of Groningen Content Abstract..............................................................................................................................................2 1.0 Peptidoglycan biosynthesis of bacteria ........................................................................................3 2.0 Novel antimicrobial agents ...........................................................................................................4 2.1 Teixobactin ...............................................................................................................................4 2.2 tridecaptin A1............................................................................................................................7 2.3 Malacidins ................................................................................................................................8 2.4 Humimycins ..............................................................................................................................9 2.5 LysM ........................................................................................................................................ 10 3.0 Concluding remarks .................................................................................................................... 11 4.0 references .................................................................................................................................
    [Show full text]
  • Parsek Micro410 Lecture
    Microm 410 Fall 2009: Prokaryotic Structure/Function part 1 Dr. Matt Parsek Organization of the Prokaryotic Cell Prokaryotic Structures fimbriae Size Range of Prokaryotes bacillus See Table 4.1 (rigid) vibrio Nanobacteria 0.05‐0.2 µm (0.14‐0.2 µm) (flexible) Thiomargarita namibiensis Mycoplasma are 700‐750 µm (Fig. 4.2) pleomorphic green alga Nanochlorum eukaryotum Mycoplasma 0.1‐ ~1-2 µm in diameter 0.3 µm Fig. 4.1 Microm 410 Fall 2009: Prokaryotic Structure/Function part 1 Dr. Matt Parsek Staining cells for Microscopic observation Cell Arrangements Motility- ~80% of prokaryotes are motile streptococcus Staining properties: Gram Stain staphylococcus Fig. 2.3 Gram Stain (1884) (Bacteria) Gram-negative mixed culture Gram-positive Fig. 2.3 and 2.4 Microm 410 Fall 2009: Prokaryotic Structure/Function part 1 Dr. Matt Parsek Functions of the cytoplasmic membrane The phospholipid bi‐layer Fig. 4.9 Fig. 4.4 What is the structure of bacterial phospholipids? Other components of the cytoplasmic membrane Figs. 4.5‐4.6 Microm 410 Fall 2009: Prokaryotic Structure/Function part 1 Dr. Matt Parsek Archaeal membranes can be a lipid monolayer Archaeal phospholipids have an ether linkage Fig. 4.7 Fig. 4.8 Importance of Cell Wall Schematic diagram cell wall • Provides rigidity to cell allowing cell to withstand the large osmotic/ionic Fig. 4.16 changes a bacterium may experience in its environment, and turgor pressure of cytoplasm (conc. of solutes in cytoplasm). Cell lysis • May have a role in shape determination. • Provides a barrier against certain toxic chemical and biological agents. • Site of action of some of the most commonly used antibiotics used to treat bacterial infections (penicillin family).
    [Show full text]
  • Parsek Lecture #3
    Microm 410 Fall 2009: Prokaryotic Structure/Function: Part 2/3 Dr. Matt Parsek Peptidoglycan Synthesis Peptidoglycan Synthesis cytoplasm cell membrane cell wall Bactoprenol-P Pi UDP-NAM M G pentapeptide G M Bactoprenol Bactoprenol-P-P P M UMP G P NAM G M pentapeptide M G UDP-NAG Bactoprenol G P NAM‐NAG P NAM-NAG UMP pentapeptide Fig. 6.7a Interbridge peptide Peptidoglycan Synthesis Cross-linking of Peptidoglycan Strands cytoplasm cell membrane cell wall autolysins Bactoprenol-P Pi UDP-NAM Bacitracin M G pentapeptide G D-cycloserine Bactoprenol M (Oxamycin) Bactoprenol-P-P P M UMP G P Transpeptidase (FtsI) NAM G M pentapeptide M G UDP-NAG Bactoprenol G Vancomycin P NAM‐NAG P NAM-NAG pentapeptide UMP Fig. 6.7b pentapeptide Interbridge peptide Microm 410 Fall 2009: Prokaryotic Structure/Function: Part 2/3 Dr. Matt Parsek Cross-linking of Peptidoglycan Strands Antibiotic Resistance autolysins • Inactivate antibiotic β-lactamase (penicillinase) Clavulanic acid β-lactams Augmentin and Trimentin (combination of clavulanic acid and transpeptidase amoxicillin or ampicillin respectively) penicillins and cephalosporins lysozyme • Change chemistry of target site • Limit access of the antibiotic to target site Fig. 6.5 Cell Shape Determination • Modifications made to Peptidoglycan: ‐ lysozyme: Protoplasts/spheroplasts ‐ autolysins Bacillus subtilis ‐ endopeptidase Heliobacter pylori • Protein(s) may play a major role ‐ MreB protein Caulobacter crescentus ‐ MreB has homology to actin, a component of the cytoskeleton of eukaryotes. Shape determining protein‐ crescentin Fig. 6.4 Microm 410 Fall 2009: Prokaryotic Structure/Function: Part 2/3 Dr. Matt Parsek Cell Wall Gram-positive Bacteria intermediate filaments in the bacteria Caulobacter crescentus glycerol similar predicted structures of crescentin and intermediate filaments Fig.
    [Show full text]
  • WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07D 519/00 (2006.01) A61P 39/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07D 487/04 (2006.01) A61P 35/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/5517 (2006.01) A61P 37/00 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, A61K 47/48 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/IB2013/058229 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 2 September 2013 (02.09.2013) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: HANGZHOU DAC BIOTECH CO., LTD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, [US/CN]; Room B2001-B2019, Building 2, No 452 Sixth TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Street, Hangzhou Economy Development Area, Hangzhou EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, City, Zhejiang 310018 (CN).
    [Show full text]
  • Antibiotic Discovery
    ANTIBIOTIC DISCOVERY RESISTANCE PROFILING OF MICROBIAL GENOMES TO REVEAL NOVEL ANTIBIOTIC NATURAL PRODUCTS By CHELSEA WALKER, H. BSc. A Thesis Submitted to the School of Graduate Studies in Partial Fulfilment of the Requirements for the Degree Master of Science McMaster University © Copyright by Chelsea Walker, May 2017 McMaster University MASTER OF SCIENCE (2017) Hamilton, Ontario (Biochemistry and Biomedical Sciences) TITLE: Resistance Profiling of Microbial Genomes to Reveal Novel Antibiotic Natural Products. AUTHOR: Chelsea Walker, H. BSc. (McMaster University) SUPERVISOR: Dr. Nathan A. Magarvey. COMMITTEE MEMBERS: Dr. Eric Brown and Dr. Michael G. Surette. NUMBER OF PAGES: xvii, 168 ii Lay Abstract It would be hard to imagine a world where we could no longer use the antibiotics we are routinely being prescribed for common bacterial infections. Currently, we are in an era where this thought could become a reality. Although we have been able to discover antibiotics in the past from soil dwelling microbes, this approach to discovery is being constantly challenged. At the same time, the bacteria are getting smarter in their ways to evade antibiotics, in the form of resistance, or self-protection mechanisms. As such is it essential to devise methods which can predict the potential for resistance to the antibiotics we use early in the discovery and isolation process. By using what we have learned in the past about how bacteria protect themselves for antibiotics, we can to stay one step ahead of them as we continue to search for new sources of antibiotics from bacteria. iii Abstract Microbial natural products have been an invaluable resource for providing clinically relevant therapeutics for almost a century, including most of the commonly used antibiotics that are still in medical use today.
    [Show full text]
  • E. Coli Pbp1b, Moenomycin-Based
    Investigating the Ligand Interactions Between E. coli PBP1b, Moenomycin-based Compounds, and Beta-Lactam Compounds Peter Alexander MSc by Research 2017 i CERTIFICATE OF ORIGINALITY This is to certify that I am responsible for the work submitted in this thesis, that the original work is my own, except as specified in the acknowledgements and in references, and that neither the thesis nor the original work contained therein has been previously submitted to any institution for a degree. Signature: Name: Date: CERTIFICATE OF COMPLIANCE This is to certify that this project has been carried out in accordance with University principles regarding ethics and health and safety. Forms are available to view on request. Signature: Name: Date: ii Abstract Antimicrobial resistance is a growing problem in this era. Resistance to the majority of clinical antibiotics including those of a ‘last line of defence’ nature has been seen in a number of laboratory and clinical settings. One method aiming at reducing this problem is altering existing antimicrobial compounds, in order to improve pharmacological effects (avoiding resistance mechanisms, improved spectrum of use). Analysis of the interactions between the antimicrobial compounds and their targets can determine whether modifications to current antimicrobials (such as moenomycin A, a glycosyltransferase inhibitor) have altered the mode of action. ecoPBP1B is a bifunctional glycosyltransferase that could be used as a model for beta lactams and moenomycins, aiding in the design and development of novel antimicrobials based on these families. Moenomycin A has not seen high clinical usage due to poor pharmacokinetics and bioavailability. This project aimed to show whether ecoPBP1b can be used as a model for novel antimicrobials, such as seeing whether Moenomycin A analogues (with cell penetrating peptides to facilitate entry into the bacterial cell) still retain their ability to bind to glycosyltransferases.
    [Show full text]
  • Lipid II: a Central Component in Bacterial Cell Wall Synthesis and a Target for Antibiotics
    ARTICLE IN PRESS Prostaglandins, Leukotrienes and Essential Fatty Acids 79 (2008) 117–121 Contents lists available at ScienceDirect Prostaglandins, Leukotrienes and Essential Fatty Acids journal homepage: www.elsevier.com/locate/plefa Lipid II: A central component in bacterial cell wall synthesis and a target for antibiotics Ben de Kruijff Ã, Vincent van Dam, Eefjan Breukink Chemical Biology and Organic Chemistry, Utrecht University, Padualaan 8, Utrecht, The Netherlands abstract The bacterial cell wall is mainly composed of peptidoglycan, which is a three-dimensional network of long aminosugar strands located on the exterior of the cytoplasmic membrane. These strands consist of alternating MurNAc and GlcNAc units and are interlinked to each other via peptide moieties that are attached to the MurNAc residues. Peptidoglycan subunits are assembled on the cytoplasmic side of the bacterial membrane on a polyisoprenoid anchor and one of the key components in the synthesis of peptidoglycan is Lipid II. Being essential for bacterial cell survival, it forms an attractive target for antibacterial compounds such as vancomycin and several lantibiotics. Lipid II consists of one GlcNAc- MurNAc-pentapeptide subunit linked to a polyiosoprenoid anchor 11 subunits long via a pyrophosphate linker. This review focuses on this special molecule and addresses three questions. First, why are special lipid carriers as polyprenols used in the assembly of peptidoglycan? Secondly, how is Lipid II translocated across the bacterial cytoplasmic membrane? And finally, how is Lipid II used as a receptor for lantibiotics to kill bacteria? & 2008 Elsevier Ltd. All rights reserved. 1. Introduction which will be discussed later. Despite considerable knowledge of cell wall synthesis several key questions remained unanswered so The bacterial cell wall is a unique structure.
    [Show full text]
  • Structural Characterization of Bacterial Defense Complex Marko Nedeljković
    Structural characterization of bacterial defense complex Marko Nedeljković To cite this version: Marko Nedeljković. Structural characterization of bacterial defense complex. Biomolecules [q-bio.BM]. Université Grenoble Alpes, 2017. English. NNT : 2017GREAV067. tel-03085778 HAL Id: tel-03085778 https://tel.archives-ouvertes.fr/tel-03085778 Submitted on 22 Dec 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE Pour obtenir le grade de DOCTEUR DE LA COMMUNAUTE UNIVERSITE GRENOBLE ALPES Spécialité : Biologie Structurale et Nanobiologie Arrêté ministériel : 25 mai 2016 Présentée par Marko NEDELJKOVIĆ Thèse dirigée par Andréa DESSEN préparée au sein du Laboratoire Institut de Biologie Structurale dans l'École Doctorale Chimie et Sciences du Vivant Caractérisation structurale d'un complexe de défense bactérienne Structural characterization of a bacterial defense complex Thèse soutenue publiquement le 21 décembre 2017, devant le jury composé de : Monsieur Herman VAN TILBEURGH Professeur, Université Paris Sud, Rapporteur Monsieur Laurent TERRADOT Directeur de Recherche, Institut de Biologie et Chimie des Protéines, Rapporteur Monsieur Patrice GOUET Professeur, Université Lyon 1, Président Madame Montserrat SOLER-LOPEZ Chargé de Recherche, European Synchrotron Radiation Facility, Examinateur Madame Andréa DESSEN Directeur de Recherche, Institut de Biologie Structurale , Directeur de These 2 Contents ABBREVIATIONS ..............................................................................................................................
    [Show full text]
  • Discovery of Wall Teichoic Acid Inhibitors As Potential Anti-MRSA &Beta
    Chemistry & Biology Article Discovery of Wall Teichoic Acid Inhibitors as Potential Anti-MRSA b-Lactam Combination Agents Hao Wang,1 Charles J. Gill,1 Sang H. Lee,1 Paul Mann,1 Paul Zuck,2 Timothy C. Meredith,3 Nicholas Murgolo,1 Xinwei She,1 Susan Kales,1 Lianzhu Liang,1 Jenny Liu,1 Jin Wu,1 John Santa Maria,4 Jing Su,1 Jianping Pan,1 Judy Hailey,1 Debra Mcguinness,1 Christopher M. Tan,1 Amy Flattery,1 Suzanne Walker,4 Todd Black,1 and Terry Roemer1,* 1Infectious Disease Biology, Merck Research Laboratories, Kenilworth, NJ 07033, USA 2Screening and Protein Science, Merck Research Laboratories, West Point, PA 19486, USA 3Infectious Diseases Area, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA 4Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA *Correspondence: [email protected] http://dx.doi.org/10.1016/j.chembiol.2012.11.013 SUMMARY bacteria (Drawz and Bonomo, 2010). Paramount to the rationale of combination agents is the increased potency and efficacy Innovative strategies are needed to combat drug achieved by their combined effects. Ideally, this is achieved resistance associated with methicillin-resistant by the synergistic bioactivity of both agents affecting two inter- Staphylococcus aureus (MRSA). Here, we investigate dependent cellular processes required for cell growth as well the potential of wall teichoic acid (WTA) biosynthesis as the targeted inactivation of the resistance mechanism to the inhibitors as combination agents to restore b-lactam first agent by the combination agent (Tan et al., 2012). Applying efficacy against MRSA. Performing a whole-cell a systems biology approach to discovering synergistic agents with this therapeutic potential is highly warranted; lethal or pathway-based screen, we identified a series of even growth-crippling chemical genetic interactions highlight WTA inhibitors (WTAIs) targeting the WTA trans- a cellular network of interdependent biological processes and porter protein, TarG.
    [Show full text]
  • Recent Advances in Design of Antimicrobial Peptides and Polypeptides Toward Clinical Translation
    Advanced Drug Delivery Reviews 170 (2021) 261–280 Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr Recent advances in design of antimicrobial peptides and polypeptides toward clinical translation Yunjiang Jiang a,b, Yingying Chen a, Ziyuan Song a, Zhengzhong Tan a, Jianjun Cheng a,b,c,d,⁎ a Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign, 1304 W Green Street, Urbana, IL 61801, United States b Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, 405 N Mathews Ave, Urbana, IL 61801, United States c Department of Bioegineering, University of Illinois at Urbana-Champaign, 1406 W Green Street, Urbana, IL 61801, United States d Department of Chemistry, University of Illinois at Urbana-Champaign, 505 S Mathews Ave, Urbana, IL 61801, United States article info abstract Article history: The recent outbreaks of infectious diseases caused by multidrug-resistant pathogens have sounded a piercing Received 9 October 2020 alarm for the need of new effective antimicrobial agents to guard public health. Among different types of Received in revised form 16 December 2020 candidates, antimicrobial peptides (AMPs) and the synthetic mimics of AMPs (SMAMPs) have attracted signifi- Accepted 28 December 2020 cant enthusiasm in the past thirty years, due to their unique membrane-active antimicrobial mechanism and Available online 02 January 2021 broad-spectrum antimicrobial activity. The extensive research has brought many drug candidates into clinical and pre-clinical development. Despite tremendous progresses have been made, several major challenges inher- Keywords: Antibiotic resistance ent to current design strategies have slowed down the clinical translational development of AMPs and SMAMPs.
    [Show full text]
  • Effect of Inhibitors of Cell Wall Synthesis on Phospholipid Composition and Metabolism in Bacillus Stearothermophilus
    University of Montana ScholarWorks at University of Montana Graduate Student Theses, Dissertations, & Professional Papers Graduate School 1984 Effect of inhibitors of cell wall synthesis on phospholipid composition and metabolism in Bacillus stearothermophilus Stuart A. Hill The University of Montana Follow this and additional works at: https://scholarworks.umt.edu/etd Let us know how access to this document benefits ou.y Recommended Citation Hill, Stuart A., "Effect of inhibitors of cell wall synthesis on phospholipid composition and metabolism in Bacillus stearothermophilus" (1984). Graduate Student Theses, Dissertations, & Professional Papers. 7390. https://scholarworks.umt.edu/etd/7390 This Thesis is brought to you for free and open access by the Graduate School at ScholarWorks at University of Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact [email protected]. COPYRIGHT ACT OF 1975 Th i s is an unpublished m a n u s c r i p t in w h i c h c o p y r i g h t s u b ­ s i s t s . Any f u r t h e r r e p r i n t i n g o f its c o n t e n t s m u s t b e a p p r o v e d BY THE AUTHOR. MANSFIELD L i b r a r y Un i v e r s i t y o f Mo n t a n a Date 1 6 THE EFFECT OF INHIBITORS OF CELL WALL SYNTHESIS ON PHOSPHOLIPID COMPOSITION AND METABOLISM IN BACILLUS STEAROTHERMDPHILUS by Stiiart A.
    [Show full text]